Volume 13, Issue 3 (9-2025)                   JoMMID 2025, 13(3): 224-230 | Back to browse issues page

Ethics code: IR.UMSU.REC.1398.324.

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mehranfar S, Yekanlou A, Heidari M, Lahouty M. Assessment of Hematological Indices as Potential Prognostic Markers in COVID-19 Patients at Taleghani Hospital, Urmia, Iran. JoMMID 2025; 13 (3) :224-230
URL: http://jommid.pasteur.ac.ir/article-1-654-en.html
Assessment of Hematological Indices as Potential Prognostic Markers in COVID-19 Patients at Taleghani Hospital, Urmia, Iran
Sahar Mehranfar , Ali Yekanlou , Mohammad Heidari , Masoud Lahouty *
Department of Microbiology and Virology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Abstract:   (1148 Views)
Introduction: Rapid and accurate diagnosis of COVID-19 is critical for effective patient management, timely treatment, and mitigating disease transmission. Identifying reliable prognostic markers, such as hematological indices, can enable prompt medical intervention and improve outcomes. This study aimed to investigate the association among mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and mean corpuscular volume (MCV), measured within the first 10 days of hospital admission, and clinical outcomes (e.g., survival vs. mortality) in COVID-19 patients. Methods: This retrospective study included 173 patients with confirmed COVID-19 (Delta variant) admitted to Taleghani Hospital in Urmia. Complete blood count (CBC) data, including hemoglobin (Hb), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), and white blood cell (WBC) counts, were extracted from electronic medical records. Differences between survivor and non-survivor groups were analyzed using ANOVA with Tukey post hoc test, with statistical significance set at P < 0.05. Results: The median age of all patients was 53 years (IQR: 22–88), with a significant difference between survivors (52 years; IQR: 22–88) and non-survivors (60 years; IQR: 35–85) (P = 0.04). Patients in the non-survivor group had a significantly higher prevalence of comorbidities compared to the survivor group. Patients with diabetes (P=0.327) or hypertension (P=0.797) did not have a significantly higher prevalence in the non-survivor group, though trends suggest possible increased mortality risk. However, no significant differences were found in Hb, MCH, and MCV between the survivor and non-survivor groups (P>0.05). Conclusions: While some hematological markers are routinely used in diagnosing various diseases, this study did not find significant differences in Hb, MCH, and MCV between survivor and non-survivor groups, suggesting these specific markers may not be reliable for early diagnosis or predicting prognosis in Delta-variant COVID-19 in this Iranian cohort. Further research with a larger sample size and including a wider range of hematological and inflammatory markers is warranted to explore the potential role of these markers in COVID-19 diagnosis and prognosis. Investigating the interplay between these markers and clinical outcomes could provide valuable insights for patient management.
 
Keywords: COVID-19, Prognosis, Hematological indices, Early diagnosis, Hospitalized patients, Mean corpuscular volume, Mean corpuscular hemoglobin
Full-Text [PDF 696 kb]   (112 Downloads)    
Type of Study: Original article | Subject: Other
Received: 2024/03/21 | Accepted: 2025/09/10 | Published: 2025/12/2
References
1. Sabbaghian M, Gheitasi H, Fadaee M, Javadi Henafard H, Tavakoli A, Shekarchi AA, et al. Human cytomegalovirus microRNAs: strategies for immune evasion and viral latency. Arch Virol. 2024; 169 (8): 157. [DOI:10.1007/s00705-024-06080-w] [PMID]
2. Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8 (5): 475-81. [DOI:10.1016/S2213-2600(20)30079-5] [PMID]
3. Gheitasi H, Sabbaghian M, Fadaee M, Mohammadzadeh N, Shekarchi AA, Poortahmasebi V. The relationship between autophagy and respiratory viruses. Arch Microbiol. 2024; 206 (4): 136. [DOI:10.1007/s00203-024-03838-3] [PMID]
4. Razimoghadam M, Yaseri M, Rezaee M, Fazaeli A, Daroudi R. Non-COVID-19 hospitalization and mortality during the COVID-19 pandemic in Iran: a longitudinal assessment of 41 million people in 2019-2022. BMC Public Health. 2024; 24 (1): 380. [DOI:10.1186/s12889-024-17819-0] [PMID] [PMCID]
5. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID‐19. Cochrane Database Syst Rev. 2022 (5): CD013665. [DOI:10.1002/14651858.CD013665.pub3] [PMID] [PMCID]
6. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146 (1): 110-8. [DOI:10.1016/j.jaci.2020.04.006] [PMID] [PMCID]
7. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systematic review and meta-analysis. Int J Infect Dis. 2020; 96: 131-5. [DOI:10.1016/j.ijid.2020.04.086] [PMID] [PMCID]
8. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46 (5): 846-8. [DOI:10.1007/s00134-020-05991-x] [PMID] [PMCID]
9. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020; 221 (11): 1762-9. [DOI:10.1093/infdis/jiaa150] [PMID] [PMCID]
10. Guan Wj, Ni Zy, Hu Y, Liang Wh, Ou Cq, He Jx, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-20. [DOI:10.1056/NEJMoa2002032] [PMID] [PMCID]
11. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020; 95: 183-91. [DOI:10.1016/j.ijid.2020.03.013] [PMID] [PMCID]
12. Zhang Jj, Dong X, Cao Yy, Yuan Yd, Yang Yb, Yan Yq, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020; 75 (7): 1730-41. [DOI:10.1111/all.14238] [PMID]
13. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395 (10223): 507-13. [DOI:10.1016/S0140-6736(20)30211-7] [PMID]
14. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2021; 73 (11): e4208-13. [DOI:10.1093/cid/ciaa270] [PMID] [PMCID]
15. Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM. 2020; 113 (7): 474-81. [DOI:10.1093/qjmed/hcaa089] [PMID] [PMCID]
16. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clinica Chimica Acta. 2020; 506: 145-8. [DOI:10.1016/j.cca.2020.03.022] [PMID] [PMCID]
17. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva: World Health Organization;2020 Feb [cited 2025 Apr 27]. Available from: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)
18. Hurwitz SJ, De R, LeCher JC, Downs-Bowen JA, Goh SL, Zandi K, et al. Why certain repurposed drugs are unlikely to be effective antivirals to treat SARS-CoV-2 infections. Viruses. 2024; 16 (4): 651. [DOI:10.3390/v16040651] [PMID] [PMCID]
19. Buoro S, Di Marco F, Rizzi M, Fabretti F, Lorini FL, Cesa S, et al. Papa Giovanni XXIII Bergamo hospital at the time of the COVID-19 outbreak: letter from the warfront. Int J Lab Hematol. 2020; 42 (Suppl 1): 8-10. [DOI:10.1111/ijlh.13207] [PMID]
20. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020; 95 (6): E131-4. [DOI:10.1002/ajh.25774]
21. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71 (15): 762-8. [DOI:10.1093/cid/ciaa248] [PMID] [PMCID]
22. Mitra A, Dwyre DM, Schivo M, Thompson GR 3rd, Cohen SH, Ku N, et al. Leukoerythroblastic reaction in a patient with COVID-19 infection. Am J Hematol. 2020; 95 (8): 999-1000. [DOI:10.1002/ajh.25793] [PMID] [PMCID]
23. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 934-43. [DOI:10.1001/jamainternmed.2020.0994] [PMID] [PMCID]
24. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-62. [DOI:10.1016/S0140-6736(20)30566-3] [PMID]
25. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55 (5): 2000524. [DOI:10.1183/13993003.00524-2020] [PMID] [PMCID]
26. Yousif NG, Altimimi AN, Al-Amran FG, Lee JA, Al-Fadhel SM, Hussien SR, et al. Hematological changes among coronavirus-19 patients: a longitudinal study. Syst Rev Pharm. 2020; 11 (5): 62-6.
27. Bahramikia S, Gavyar PHH, Amiri S. Evaluation of different biochemical factors in patients with coronavirus disease in Imam Khomeini hospital of Selseleh County (Lorestan Province). Jundishapur Scientific Medical Journal. 2022; 20 (6): 528-35. [DOI:10.32598/JSMJ.20.6.2254]
28. Jalil AT, Shanshool MT, Dilfy SH, Saleh MM, Suleiman AA. Hematological and serological parameters for detection of COVID-19. J Microbiol Biotechnol Food Sci. 2021; 10 (4): e4555. [DOI:10.55251/jmbfs.4229]
29. Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y, et al. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin Med. 2020; 15: 34. [DOI:10.1186/s13020-020-00317-x] [PMID] [PMCID]
30. Wang C, Zhang H, Cao X, Deng R, Ye Y, Fu Z, et al. Red cell distribution width (RDW): a prognostic indicator of severe COVID-19. Ann Transl Med. 2020; 8 (19): 1230. [DOI:10.21037/atm-20-6090] [PMID] [PMCID]
31. Zini G, Bellesi S, Ramundo F, d'Onofrio G. Morphological anomalies of circulating blood cells in COVID‐19. Am J Hematol. 2020; 95 (7): 870-2. [DOI:10.1002/ajh.25824] [PMID] [PMCID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.